All News

Assessment of MAP kinase pathway gene expression prior to tx may aid in identification of polyarticular course JIA patients that could exhibit poor response to tofacitinib. It may be helpful in personalized tx algorithm! #ACR23 Abs #0830 https://t.co/Z8pykbG7x5 @rheumnow https://t.co/ANZr8aVrVB
Dr. Rachel Tate  ( View Tweet)
STOP-JIA study data from Abs #0831 suggest improved effectiveness with early combination tx vs step up and biologic first tx at the 2-3 yr timeframe for pJIA pts. More data needed to optimize outcomes/tx for these children. https://t.co/vWL5J4FPbo #ACR23 @rheumnow https://t.co/5iJpwglhPu
Dr. Rachel Tate  ( View Tweet)
Good Treatment review of biologics (IL-1, IL-6) in systemic JIA (Stills) including complications of #MAS and lung disease; also info on horizon therapies like JAK inhibitors and IL-18 targeting and novel biomarkers (calgranulins, IL-18 and CXCL9) https://t.co/Cbd7bKdIbb https://t.co/d9tn9fmSAy

Links:

Dr. John Cush RheumNow ( View Tweet)
Things for me to take back to the clinic in looking after JIA patients, Sadun R, #ACR23 @RheumNow https://t.co/YkiP4GZG19
Dr. Antoni Chan  ( View Tweet)
New clinical skill to use in the clinic. Auscultate at the TMJ for crepitus and measure the maximal incisal opening in JIA, Sadun R, #ACR23 @RheumNow https://t.co/8koZRCZYoP
Dr. Antoni Chan  ( View Tweet)
RheumNow Podcast square

ACR Convergence Preview (11.10.2023)

d Jack Cush, MD

Dr. Jack Cush reviews this past week's news on RheumNow.com and suggests a learning plan for those wanting to consume the upcoming ACR Convergence 2023 meeting. 

Read Article
Anakinra Effective in Systemic JIA, Irrespective of HLA-DRB1 and IL1RN Variants A prospective study of first line use anakinra in systemic juvenile idiopathic arthritis (sJIA) proved to be effective and without potentially allergic lung reactions. https://t.co/MRFwrCXIlQ https://t.co/Su3nMs4CNW

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Late Should Not Be Less (11.3.2023)

d Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and regulatory approvals from the past week on RheumNow.com.

Read Article
FDA has approved Abatacept to Treat Juvenile Psoriatic Arthritis (JPsA) in patients aged 2 to 17 years. (JPsA) in patients aged 2 to 17 years. This expands the current indications for ABA use in RA, poly JIA, PsA, and GVHD. https://t.co/eAc8Dsyc3b https://t.co/uHJqhEvuPG

Links:

Dr. John Cush RheumNow ( View Tweet)
Anifrolumab was studied in 7 adolescents w/ resistant #DLE (discoid); given 6 monthly IV doses. All had signif decreases in skin CLASI-A scores (72%) at 1 month (P =.01), sustained at 6-mo F/U. SLEDAI-2K score also decr by 7 pts; 1 had HSV-1 reactivation https://t.co/Nc0IN1Rsao https://t.co/XeAB99YZMF

Links:

Dr. John Cush RheumNow ( View Tweet)
Hepatotoxicity related to Anakinra has been reported in pediatric rheumatology patients. LFT elevations have been reported with IL-1 inhibition, even after excluding LFTs from the inflamm Dx, other drugs, MAS, etc. Here are 3 case reports. https://t.co/6ZxIcHbUEd https://t.co/Cx0kbn7JU2

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Sleep Apnea Smart Watches (10.13.2023)

d Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com.

Read Article
FDA Approves the first Actemra biosimilar- called tocilizumab-bavi (Tofidence) or BIIB800 (during development). This IV FORMULATION is approved for use in active RA, polyarticular JIA and systemic JIA. https://t.co/SSKz6RcR5r https://t.co/fLSNHazFS6 https://t.co/pvfrjkOeyW… https://t.co/ASihH17Phu

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA Approves the first Actemra biosimilar- called tocilizumab-bavi (Tofidence) or BIIB800 (during development). This IV FORMULATION is approved for use in active RA, polyarticular JIA and systemic JIA. https://t.co/SSKz6RcR5r https://t.co/fLSNHazFS6 https://t.co/pvfrjkOeyW… https://t.co/ASihH17Phu

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA Approves the first Actemra biosimilar- called tocilizumab-bavi (Tofidence) or BIIB800 (during development). This IV FORMULATION is approved for use in active RA, polyarticular JIA and systemic JIA. https://t.co/SSKz6RcR5r https://t.co/fLSNHazFS6 https://t.co/pvfrjkOeyW… https://t.co/ASihH17Phu

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Hard Decisions in RA (9.1.2023)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow, and introduces our September campaign - "Hard Decisions in RA".

Read Article
microbiome,blue

Gut Microbiome Differences Antedate JIA Development

d Jack Cush, MD

Researchers have shown that gut microbiome differences may be associated with later development of juvenile idiopathic arthritis (JIA), and that such differences are present years before the disease is diagnosed.

Read Article
JIA_0.jpg

Monoarticular JIA - a Distinct Clinical Entity

d Jack Cush, MD

Monoarticular Juvenile Idiopathic Arthritis (monoJIA) is typically classified under oligoarticular JIA, but a recent study suggests it is a separate entity.

Read Article
RheumNow Podcast square

Pizza and Rheumatoid Arthritis (8.11.2023)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the wonderful wide world of Rheumatology. This week:

Read Article
RheumNow Podcast square

English for the Biologically-Challenged (8.4.2023)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  This week highlights Veterans, Vegetarians and Antenatal Corticosteroids.

Read Article

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.